Table III.
Incidence, severity, onset, and duration of CRS and NEs.
| TEAE | Cohort 6 (n = 40) |
|---|---|
| CRS | |
| Any, n (%) | 32 (80) |
| Worst grade 1, n (%) | 14 (35) |
| Worst grade 2, n (%) | 18 (45) |
| Worst grade 3, n (%) | 0 |
| Worst grade 4, n (%) | 0 |
| Worst grade 5, n (%) | 0 |
| Median (range) time to onset of any‐grade CRS, days | 5·0 (1–15) |
| Median (range) duration, days | 4·0 (1–11) |
| Neurologic events | |
| Any, n (%) | 23 (58) |
| Worst grade 1, n (%) | 10 (25) |
| Worst grade 2, n (%) | 8 (20) |
| Worst grade 3, n (%) | 3 (8) |
| Worst grade 4, n (%) | 2 (5) |
| Worst grade 5, n (%) | 0 |
| Median (range) time to onset of any‐grade NE, days | 6·0 (2–162) |
| Median (range) duration, days | 18·5 (1–103) |
CRS, cytokine release syndrome; NE, neurologic event; TEAE, treatment‐emergent adverse event.